Compare SYRE & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYRE | BLCO |
|---|---|---|
| Founded | 2013 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.9B |
| IPO Year | 2015 | 2022 |
| Metric | SYRE | BLCO |
|---|---|---|
| Price | $71.71 | $16.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $85.08 | $18.45 |
| AVG Volume (30 Days) | ★ 1.3M | 381.1K |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $5,101,000,000.00 |
| Revenue This Year | N/A | $8.65 |
| Revenue Next Year | N/A | $5.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $12.29 | $10.85 |
| 52 Week High | $76.00 | $18.92 |
| Indicator | SYRE | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 62.72 | 46.44 |
| Support Level | $30.39 | $14.39 |
| Resistance Level | $74.92 | $17.11 |
| Average True Range (ATR) | 4.18 | 0.49 |
| MACD | -0.78 | 0.01 |
| Stochastic Oscillator | 43.70 | 37.90 |
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.